A5062922464- Adenosine and Purinergic Signaling
- Tryptophan and brain disorders
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Biochemical Analysis and Sensing Techniques
- RNA Interference and Gene Delivery
- IL-33, ST2, and ILC Pathways
- Immune cells in cancer
- Chronic Lymphocytic Leukemia Research
- Olfactory and Sensory Function Studies
- Eosinophilic Disorders and Syndromes
- Hematopoietic Stem Cell Transplantation
- Adolescent and Pediatric Healthcare
- Stress Responses and Cortisol
- Mesenchymal stem cell research
- Advanced Chemical Sensor Technologies
- Protease and Inhibitor Mechanisms
- T-cell and B-cell Immunology
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Bipolar Disorder and Treatment
- CAR-T cell therapy research
Istituto di Ematologia di Bologna
2022-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2024
Policlinico S.Orsola-Malpighi
2007-2021
University of Bologna
2012-2021
Istituto Oncologico Romagnolo
2008
Abstract Group 2 innate lymphoid cells (ILC2s) are involved in human diseases, such as allergy, atopic dermatitis and nasal polyposis, but their function cancer remains unclear. Here we show that, acute promyelocytic leukaemia (APL), ILC2s increased hyper-activated through the interaction of CRTH2 NKp30 with elevated tumour-derived PGD2 B7H6, respectively. ILC2s, turn, activate monocytic myeloid-derived suppressor (M-MDSCs) via IL-13 secretion. Upon treating APL all-trans retinoic acid...
Abstract It has been reported that ATP inhibits or stimulates lymphoid cell proliferation depending on the cellular subset analyzed. In this study, we show exerts strikingly opposite effects anti-CD3/CD28–activated and regulatory CD4+ T cells (Tregs), based nucleotide concentration. We demonstrate physiological concentrations of extracellular (1–50 nM) do not affect activated Tregs. Conversely, higher have a bimodal effect cells. Whereas 250 nM proliferation, cytokine release, expression...
Extracellular nucleotides are potent signaling molecules mediating cell-specific biological functions, mostly within the processes of tissue damage and repair flogosis. We previously demonstrated that adenosine 5'-triphosphate (ATP) inhibits proliferation human bone marrow-derived mesenchymal stem cells (BM-hMSCs), while stimulating, in vitro vivo, their migration. Here, we investigated effects ATP on BM-hMSC differentiation capacity. Molecular analysis showed treatment modulated expression...
The immunoregulatory enzyme indoleamine 2,3-dioxygenase, which catalyzes the conversion of tryptophan into kynurenine, is expressed in a significant subset patients with acute myeloid leukemia, resulting inhibition T-cell proliferation and induction regulatory T cells. Acute leukemia cells can be differentiated dendritic cells, have increased immunogenicity been proposed as vaccines against leukemia.Leukemic were generated from used stimulators functional assays, including Indoleamine...
Chemotherapy-induced immunogenic cell death can favor dendritic cross-priming of tumor-associated antigens for T activation thanks to the release damage-associated molecular patterns, including ATP. Here, we tested hypothesis that in acute myeloid leukemia, ATP release, along with its well-known immune stimulatory effect, may also contribute generation an suppressive microenvironment. In a cohort leukemia patients, undergoing combined daunorubicin and cytarabine chemotherapy, population...
Abstract Acute myeloid leukemia (AML) is a common adult often arising from preexistent myelodysplastic syndrome (MDS). High mortality rates of AML are caused by relapse and chemoresistance; therefore, we analyzed the role P2X7 receptor (P2X7R) splice variants A B in progression response to chemotherapy. The expression P2X7RA P2X7RB was investigated samples obtained MDS untreated subjects or patients remission after Both were overexpressed versus suggesting disease-promoting function....
Abstract Dendritic cells (DCs) are professional APCs that have a role in the initiation of adaptive immune responses and tolerance. Among tolerogenic mechanisms, expression enzyme IDO1 represents an effective tool to generate T regulatory cells. In humans, different DC subsets express IDO1, but less is known about IDO1-related IDO2. this study, we found pattern regulation between IDO2 human circulating DCs. At protein level, expressed only myeloid DCs (mDCs) modulated by PGE2, whereas both...
Key Points Human ILC1-like cells kill tumors in a KIR-independent manner. The cytotoxicity of human is impaired AML at diagnosis but restored remission.
We and others have shown that the Tissue Inhibitor of Metalloproteinases-1 (TIMP-1), a member inflammatory network exerting pleiotropic effects in bone marrow (BM) microenvironment, regulates survival proliferation different cell types, including normal hematopoietic progenitor cells. Moreover, TIMP-1 has been to be involved cancer progression. However, its role leukemic microenvironment not addressed. Here, we investigated activity on Acute Myelogenous Leukemia (AML) functions. First, found...
The development of Imatinib mesylate (IM), which targets the oncogenic BCR-ABL fusion protein, has greatly improved outcome Chronic Myeloid Leukemia (CML) patients. However, BCR-ABL-positive progenitors can be detected in CML patients complete cytogenetic response. Several evidence suggests that stem cells are intrinsically resistant to Tyrosine Kinase Inhibitors (TKI), and therefore they represent most likely candidate responsible for disease relapse.In this work, we investigated microRNA...
Article25 April 2022Open Access Transparent process c-Maf enforces cytokine production and promotes memory-like responses in mouse human type 2 innate lymphoid cells Sara Trabanelli Departement of Oncology, UNIL-CHUV, Ludwig Institute for Cancer Research Lausanne, University Switzerland Contribution: Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Writing - original draft, review & editing Search more papers by this author Giuseppe Ercolano...
Acute myeloid leukemia (AML) is an aggressive heterogeneous disease characterized by several alterations of the immune system prompting progression and treatment response. The therapies available for AML can affect lymphocyte function, limiting efficacy immunotherapy while hindering leukemia-specific reactions. Recently, based on Venetoclax (VEN), a specific B-cell lymphoma 2 (BCL-2) inhibitor, in combination with hypomethylating agents (HMAs) or low-dose cytarabine, has emerged as promising...
// Valentina Salvestrini 1 , Stefania Orecchioni 2 Giovanna Talarico Francesca Reggiani Cristina Mazzetti 3 Francesco Bertolini Elisa Orioli 4 Elena Adinolfi Di Virgilio Annalisa Pezzi Michele Cavo Roberto M Lemoli 5, * Antonio Curti 1, Department of Experimental, Diagnostic and Specialty Medicine, University Bologna, Italy European Institute Oncology, Milan, Biomedical Neuromotor Sciences, Morphology, Surgery Experimental Ferrara, 5 Clinic Hematology, Internal Medicine (DiMI), Genoa, These...
In the last years, dendritic cells (DC) have been evaluated for antitumor vaccination. Although DC-based vaccines raised great expectations, their clinical translation has largely disappointing. For these results, several explanations proposed. particular, concomitant expression by DCs of tolerogenic pathways, such as immunosuppressive agent indoleamine 2,3-dioxygenase-1 (IDO1), demonstrated. The aim this study is to evaluate both stimulatory and feature monocyte-derived (Mo-DCs) after...
ABSTRACT Background The management of acute myeloid leukemia (AML) is hindered by treatment‐related toxicities and complications, particularly cytopenia, which remains a leading cause mortality. Given the pivotal role gut microbiota (GM) in hemopoiesis immune regulation, we investigated its impact on hematologic recovery during AML induction therapy. Methods We profiled GM 27 newly diagnosed adult patients using 16S rRNA amplicon sequencing correlated it with key clinical parameters before...